ESR1 and breast carcinoma: Current therapeutic regimens for breast cancer include chemotherapeutic drugs such as doxorubicin, targeted agents like selective estrogen receptor modulators (e.g., raloxifene), monoclonal antibodies, and poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib (15, 16).